{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:40:07Z","timestamp":1758937207207,"version":"3.44.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016045","name":"University of Central Punjab","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016045","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.leukres.2021.106641","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T04:31:44Z","timestamp":1623385904000},"page":"106641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Novel pharmacological approach for the prevention of multidrug resistance (MDR) in a human leukemia cell line"],"prefix":"10.1016","volume":"109","author":[{"given":"Sonu Kumar","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2734-7368","authenticated-orcid":false,"given":"Ravindresh","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2395-6086","authenticated-orcid":false,"given":"Malkhey","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2021.106641_bib0005","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.exphem.2013.11.006","article-title":"Single-cell analysis of K562 cells: an imatinib-resistant subpopulation is adherent and has upregulated expression of BCR-ABL mRNA and protein","volume":"42","author":"Karimiani","year":"2014","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.leukres.2021.106641_bib0010","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1039\/c3ib20230e","article-title":"Mathematical modelling of miRNA mediated BCR. ABL protein regulation in chronic myeloid leukaemia vis-a-vis therapeutic strategies","volume":"5","author":"Verma","year":"2013","journal-title":"Integr. Biol."},{"year":"2017","series-title":"California Cancer Facts & Figures (2017)","author":"American Cancer Society CDoPH","key":"10.1016\/j.leukres.2021.106641_bib0015"},{"key":"10.1016\/j.leukres.2021.106641_bib0020","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3109\/10428190903332486","article-title":"Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions","volume":"50","author":"Markose","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2021.106641_bib0025","article-title":"Management of chronic myeloid leukemia patients resistant to tyrosine kinase inhibitors treatment","volume":"10","author":"Wieczorek","year":"2015","journal-title":"Biomark. Insights"},{"key":"10.1016\/j.leukres.2021.106641_bib0030","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1084\/jem.183.3.811","article-title":"Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr\/Abl","volume":"183","author":"Carlesso","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.leukres.2021.106641_bib0035","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","article-title":"P210 and P190BCR\/ABL induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members","volume":"271","author":"Ilaria","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2021.106641_bib0040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","author":"Chereda","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2021.106641_bib0045","first-page":"250","article-title":"One of the mechanisms in blastic transformation of chronic myeloid leukemia: epigenetics abnormality\u2014review","volume":"24","author":"Meng","year":"2016","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.leukres.2021.106641_bib0050","doi-asserted-by":"crossref","first-page":"58","DOI":"10.21276\/apjhs.2019.6.1.9","article-title":"Therapeutic approaches to enhance the BCR-ABL tyrosine kinase inhibitors efficacy in chronic myeloid leukemia","volume":"6","author":"Gupta","year":"2019","journal-title":"Asian Pacific J. Health Sci."},{"key":"10.1016\/j.leukres.2021.106641_bib0055","first-page":"1517","volume":"94","author":"Silver","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106641_bib0060","first-page":"8","article-title":"Chronic myeloid leukaemia in the 21st century","volume":"76","author":"Frazer","year":"2007","journal-title":"Ulster Med. J."},{"key":"10.1016\/j.leukres.2021.106641_bib0065","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.leukres.2021.106641_bib0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia","volume":"105","author":"Druker","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.leukres.2021.106641_bib0075","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106641_bib0080","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2021.106641_bib0085","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2021.106641_bib0090","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","article-title":"Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance","volume":"18","author":"Hochhaus","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2021.106641_bib0095","first-page":"4","article-title":"Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients","author":"Elias","year":"2012","journal-title":"Hematol. Rep."},{"key":"10.1016\/j.leukres.2021.106641_bib0100","doi-asserted-by":"crossref","first-page":"1000106","DOI":"10.4172\/2329-6917.1000106","article-title":"Abl kinase domain mutations in imatinib-treated Egyptian patients with chronic myeloid leukemia","volume":"1","author":"Elnahass","year":"2013","journal-title":"J Leuk"},{"key":"10.1016\/j.leukres.2021.106641_bib0105","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/1078-0432.CCR-06-2147","article-title":"Important therapeutic targets in chronic myelogenous leukemia","volume":"13","author":"Kantarjian","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2021.106641_bib0110","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000336610","article-title":"Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia","volume":"127","author":"Nardinelli","year":"2012","journal-title":"Acta Haematol."},{"key":"10.1016\/j.leukres.2021.106641_bib0115","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2021.106641_bib0120","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1\u2013positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106641_bib0125","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106641_bib0130","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4161\/cbt.4.7.1826","article-title":"Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps","volume":"4","author":"Burger","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.leukres.2021.106641_bib0135","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1134\/S0006297908010045","article-title":"Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib","volume":"73","author":"Stromskaya","year":"2008","journal-title":"Biochemistry (Moscow)"},{"key":"10.1016\/j.leukres.2021.106641_bib0140","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1042\/BSR20130067","article-title":"Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR\u2013CML cell lines?","volume":"33","author":"Rumjanek","year":"2013","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.leukres.2021.106641_bib0145","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification","volume":"95","author":"le Coutre","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106641_bib0150","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1359-6446(04)03275-1","article-title":"High-throughput drug discovery: what can we expect from HTS?","volume":"1","author":"Gribbon","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.leukres.2021.106641_bib0155","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1021\/jm034078c","article-title":"Identification of \u201clatent hits\u201d in compound screening collections","volume":"46","author":"Mestres","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.leukres.2021.106641_bib0160","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd2796","article-title":"The influence of lead discovery strategies on the properties of drug candidates","volume":"8","author":"Keseru","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.leukres.2021.106641_bib0165","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0006-2952(00)00297-5","article-title":"Induction of erythroid differentiation of human K562 cells by cisplatin analogs","volume":"60","author":"Bianchi","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.leukres.2021.106641_bib0170","doi-asserted-by":"crossref","first-page":"113937","DOI":"10.1016\/j.ab.2020.113937","article-title":"Optimization and application of MTT assay in determining density of suspension cells","volume":"610","author":"Nga","year":"2020","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.leukres.2021.106641_bib0175","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.canlet.2013.06.023","article-title":"Polyphenol tri-vanillic ester 13c inhibits P-JAK2V617F and Bcr\u2013Abl oncokinase expression in correlation with STAT3\/STAT5 inactivation and apoptosis induction in human leukemia cells","volume":"340","author":"Tr\u00e9cul","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.leukres.2021.106641_bib0180","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/bdd.2022","article-title":"TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp\u2010and BCRP\u2010mediated efflux","volume":"37","author":"D\u2019Cunha","year":"2016","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.leukres.2021.106641_bib0185","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/leu.2016.179","article-title":"The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment","volume":"31","author":"Eadie","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2021.106641_bib0190","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.leukres.2013.06.014","article-title":"XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells","volume":"37","author":"Silva","year":"2013","journal-title":"Leuk. Res."},{"year":"2011","series-title":"Handb. Exp. Pharmacol.","author":"Cascorbi","key":"10.1016\/j.leukres.2021.106641_bib0195"},{"key":"10.1016\/j.leukres.2021.106641_bib0200","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.taap.2004.10.012","article-title":"Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense","volume":"204","author":"Leslie","year":"2005","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.leukres.2021.106641_bib0205","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0014-5793(00)01823-8","article-title":"M-ABC2, a new human mitochondrial ATP-binding cassette membrane protein","volume":"478","author":"Zhang","year":"2000","journal-title":"FEBS Lett."},{"key":"10.1016\/j.leukres.2021.106641_bib0210","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/cdd.2011.195","article-title":"The mitochondrial transporter ABC-me (ABCB10), a downstream target of GATA-1, is essential for erythropoiesis in vivo","volume":"19","author":"Hyde","year":"2012","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.leukres.2021.106641_bib0215","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCRESAHA.113.301552","article-title":"ATP-binding cassette B10 regulates early steps of heme synthesis","volume":"113","author":"Bayeva","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.leukres.2021.106641_bib0220","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2141.2011.08936.x","article-title":"Human mitochondrial ATP\u2010binding cassette transporter ABCB10 is required for efficient red blood cell development","volume":"157","author":"Tang","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2021.106641_bib0225","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1128\/MCB.00865-13","article-title":"Abcb10 role in heme biosynthesis in vivo: Abcb10 knockout in mice causes anemia with protoporphyrin IX and iron accumulation","volume":"34","author":"Yamamoto","year":"2014","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.leukres.2021.106641_bib0230","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J","article-title":"Multidrug resistance mediated by the ATP\u2010binding cassette transporter protein MRP","volume":"20","author":"Cole","year":"1998","journal-title":"Bioessays"},{"key":"10.1016\/j.leukres.2021.106641_bib0235","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0026-895X(24)23190-4","article-title":"Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells","volume":"55","author":"Cui","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.leukres.2021.106641_bib0240","doi-asserted-by":"crossref","first-page":"6914","DOI":"10.1073\/pnas.96.12.6914","article-title":"MRP3, an organic anion transporter able to transport anti-cancer drugs","volume":"96","author":"Kool","year":"1999","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.leukres.2021.106641_bib0245","first-page":"357","article-title":"Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs","volume":"54","author":"Grant","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2021.106641_bib0250","doi-asserted-by":"crossref","first-page":"8822","DOI":"10.1073\/pnas.91.19.8822","article-title":"The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump","volume":"91","author":"Zaman","year":"1994","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.leukres.2021.106641_bib0255","doi-asserted-by":"crossref","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","article-title":"A multidrug resistance transporter from human MCF-7 breast cancer cells","volume":"95","author":"Doyle","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.leukres.2021.106641_bib0260","doi-asserted-by":"crossref","first-page":"106231","DOI":"10.1016\/j.leukres.2019.106231","article-title":"Chronic myeloid leukaemia: the dangers of not knowing your BCR-ABL1 transcript","volume":"87","author":"Sharplin","year":"2019","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2021.106641_bib0265","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621001429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621001429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:01:27Z","timestamp":1758934887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212621001429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":53,"alternative-id":["S0145212621001429"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106641","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel pharmacological approach for the prevention of multidrug resistance (MDR) in a human leukemia cell line","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106641"}}